MX2011008348A - Proceso para producir derivado heterociclico sustituido con fenilo a traves de acoplamiento usando catalizador de metal de transicion. - Google Patents

Proceso para producir derivado heterociclico sustituido con fenilo a traves de acoplamiento usando catalizador de metal de transicion.

Info

Publication number
MX2011008348A
MX2011008348A MX2011008348A MX2011008348A MX2011008348A MX 2011008348 A MX2011008348 A MX 2011008348A MX 2011008348 A MX2011008348 A MX 2011008348A MX 2011008348 A MX2011008348 A MX 2011008348A MX 2011008348 A MX2011008348 A MX 2011008348A
Authority
MX
Mexico
Prior art keywords
coupling
transition metal
metal catalyst
substituted heterocyclic
heterocyclic derivative
Prior art date
Application number
MX2011008348A
Other languages
English (en)
Inventor
Naoki Yajima
Masato Komiyama
Masayuki Kurokawa
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of MX2011008348A publication Critical patent/MX2011008348A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un proceso para producir eficientemente, a través de pocos pasos, ya sea un inhibidor de xantina oxidasa, que sea un agente terapéutico para hiperuricemia, o un intermediario del mismo. El proceso es un proceso novedoso de acoplamiento que comprende someter un compuesto representado por la fórmula (1) a reacción de acoplamiento con un compuesto representado por la fórmula (2) en presencia de un compuesto de metal de transición para así obtener un compuesto representado por la fórmula (3).
MX2011008348A 2009-02-27 2010-02-26 Proceso para producir derivado heterociclico sustituido con fenilo a traves de acoplamiento usando catalizador de metal de transicion. MX2011008348A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009046003 2009-02-27
JP2009153770 2009-06-29
PCT/JP2010/053043 WO2010098428A1 (ja) 2009-02-27 2010-02-26 遷移金属触媒を用いたカップリング法によるフェニル置換複素環誘導体の製造法

Publications (1)

Publication Number Publication Date
MX2011008348A true MX2011008348A (es) 2011-09-01

Family

ID=42665632

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008348A MX2011008348A (es) 2009-02-27 2010-02-26 Proceso para producir derivado heterociclico sustituido con fenilo a traves de acoplamiento usando catalizador de metal de transicion.

Country Status (19)

Country Link
US (1) US8952174B2 (es)
EP (2) EP2404908B1 (es)
JP (1) JP5312570B2 (es)
KR (1) KR101639834B1 (es)
CN (1) CN102333765B (es)
AU (1) AU2010218748B2 (es)
BR (1) BRPI1008308B8 (es)
CA (1) CA2752485C (es)
DK (1) DK2404908T3 (es)
ES (1) ES2459722T3 (es)
HK (1) HK1162501A1 (es)
IL (1) IL214302A (es)
MX (1) MX2011008348A (es)
PL (1) PL2404908T3 (es)
PT (1) PT2404908E (es)
RU (1) RU2510393C9 (es)
SG (1) SG173884A1 (es)
TW (1) TWI466874B (es)
WO (1) WO2010098428A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012026565A1 (ja) * 2010-08-27 2012-03-01 帝人ファーマ株式会社 パラジウム化合物を用いたカップリング法によるフェニル置換複素環誘導体の製造法
CN102234253B (zh) * 2011-06-02 2013-07-03 重庆莱美药业股份有限公司 一种制备非布索坦中间体的方法
CN103910694B (zh) * 2012-12-29 2016-08-24 广东东阳光药业有限公司 一种2-芳基腈噻唑衍生物的制备方法
AU2015260294A1 (en) * 2014-05-13 2017-01-05 Teijin Pharma Limited Novel crystalline polymorph of pyridine derivative, and method for producing same
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
CN110066258A (zh) * 2018-01-23 2019-07-30 湘北威尔曼制药股份有限公司 噻唑-5-甲酸衍生物及其制备方法与应用
CN109293597B (zh) * 2018-10-29 2022-05-10 安徽省庆云医药股份有限公司 一种非布索坦的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346094A (en) 1980-09-22 1982-08-24 Eli Lilly And Company 3-Aryl-5-isothiazolecarboxylic acids and related compounds used to lower uric acid levels
US4495195A (en) 1982-11-01 1985-01-22 Eli Lilly And Company Xanthine oxidase inhibiting 3(5)-phenyl-substituted-5(3)-pyrazole-carboxylic acid derivatives, compositions, and methods of use
JP2591632B2 (ja) 1987-12-18 1997-03-19 株式会社トプコン 真空吸引装置
CA2073981C (en) 1990-11-30 2002-01-08 Shiro Kondo 2-arylthiazole derivatives and pharmaceutical composition thereof
JP3399559B2 (ja) 1992-08-12 2003-04-21 帝人株式会社 ２−フェニル複素環式化合物
JP3113110B2 (ja) 1993-01-19 2000-11-27 帝人株式会社 イソキサゾールおよびイソチアゾール誘導体
JP3169735B2 (ja) 1993-04-08 2001-05-28 帝人株式会社 （アルコキシシアノフェニル）チアゾール誘導体の製造方法
JP2706037B2 (ja) 1993-04-13 1998-01-28 帝人株式会社 シアノ化合物およびその製造方法
JP2834971B2 (ja) 1993-05-25 1998-12-14 帝人株式会社 ２−（４−アルコキシ−３−シアノフェニル）チアゾール誘導体の製造法およびその新規製造中間体
ID21775A (id) 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
JPH10139770A (ja) 1996-11-08 1998-05-26 Teijin Ltd ２−（３−シアノフェニル）チアゾール誘導体の製造法
JPH10310578A (ja) 1996-11-13 1998-11-24 Yoshitomi Pharmaceut Ind Ltd ３−フェニルピラゾール化合物
JP3440196B2 (ja) 1997-08-13 2003-08-25 帝人株式会社 チオベンズアミド誘導体の製造方法
US6458819B1 (en) 2000-02-23 2002-10-01 Alteon, Inc. Thiazolium compounds and treatments of disorders associated with protein aging
JPWO2002051849A1 (ja) 2000-12-26 2004-04-22 第一製薬株式会社 Ｃｄｋ４活性阻害剤
PE20030968A1 (es) * 2002-02-28 2004-01-12 Novartis Ag Derivados de 5-feniltiazol como inhibidores de cinasas
KR20050101200A (ko) * 2003-02-10 2005-10-20 버텍스 파마슈티칼스 인코포레이티드 Ｎ-아릴 카밤산 에스테르를 할로-헤테로아릴과반응시킴으로써 ｎ-헤테로아릴-ｎ-아릴-아민을 제조하는방법 및 유사 방법
AU2004272599A1 (en) 2003-09-06 2005-03-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2005075435A1 (en) 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
DE602005016272D1 (de) 2004-08-27 2009-10-08 Astellas Pharma Inc 2-phenylpyridinderivat
AU2006300422A1 (en) * 2005-10-07 2007-04-19 Astellas Pharma Inc. Triarylcarboxylic acid derivative
WO2007097403A1 (ja) * 2006-02-24 2007-08-30 Astellas Pharma Inc. 消化管潰瘍治療又は予防薬
JP2012096999A (ja) * 2009-02-27 2012-05-24 Nagoya Univ ニッケル触媒を用いたカップリング法によるフェニル置換複素環誘導体の製造法
WO2012026565A1 (ja) * 2010-08-27 2012-03-01 帝人ファーマ株式会社 パラジウム化合物を用いたカップリング法によるフェニル置換複素環誘導体の製造法

Also Published As

Publication number Publication date
KR101639834B1 (ko) 2016-07-14
RU2510393C2 (ru) 2014-03-27
RU2510393C9 (ru) 2014-08-27
PT2404908E (pt) 2014-06-23
US20110313169A1 (en) 2011-12-22
EP2404908A1 (en) 2012-01-11
TW201041859A (en) 2010-12-01
IL214302A0 (en) 2011-09-27
KR20110120896A (ko) 2011-11-04
RU2011139307A (ru) 2013-04-10
US8952174B2 (en) 2015-02-10
HK1162501A1 (en) 2012-08-31
PL2404908T3 (pl) 2014-12-31
CA2752485C (en) 2017-01-03
ES2459722T3 (es) 2014-05-12
WO2010098428A1 (ja) 2010-09-02
BRPI1008308B8 (pt) 2021-05-25
TWI466874B (zh) 2015-01-01
EP2754658A1 (en) 2014-07-16
DK2404908T3 (da) 2014-04-28
BRPI1008308A2 (pt) 2016-02-23
IL214302A (en) 2014-09-30
JPWO2010098428A1 (ja) 2012-09-06
CA2752485A1 (en) 2010-09-02
AU2010218748B2 (en) 2015-03-26
CN102333765A (zh) 2012-01-25
CN102333765B (zh) 2015-01-14
EP2404908A4 (en) 2012-08-15
JP5312570B2 (ja) 2013-10-09
BRPI1008308B1 (pt) 2020-03-31
SG173884A1 (en) 2011-10-28
AU2010218748A1 (en) 2011-08-11
EP2404908B1 (en) 2014-04-09

Similar Documents

Publication Publication Date Title
MX2011008348A (es) Proceso para producir derivado heterociclico sustituido con fenilo a traves de acoplamiento usando catalizador de metal de transicion.
IL196894A0 (en) Process for preparing 3-dihalomethylpyrazole-4-carboxylic acid derivatives
WO2007035629A3 (en) Process for the preparation of pyrimidinedione derivatives
NZ594864A (en) Method of preparing an inhibitor of cytochrome p450 monooxygenase, and intermediates involved
MX2010008899A (es) Procedimiento para la sintesis regioselectiva de derivados de acido 1-alquil-3-haloalquil-pirazol-4-carboxilico.
WO2008055814A3 (en) Process for the preparation of (s)-4-fluoromethyl-dihydro-furan-2-one
NZ592497A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
WO2010085377A3 (en) Hydroxamic acid derivatives
GEP20125512B (en) Process for synthesis of agomelatin
UA101835C2 (uk) Спосіб отримання похідних 1-(2-галогенбіфеніл-4-іл)-циклопропанкарбонової кислоти
NZ593172A (en) 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2
TW200738621A (en) Chemical process
IN2012DN01273A (es)
WO2009066735A1 (ja) ２－アザアダマンタン類の製造方法
PT2462098E (pt) Processos para a preparação de derivados de ácido 1-(2- halobifenil-4-il)-ciclopropanocarboxílico
PL1851322T3 (pl) Sposób enancjoselektywnej redukcji enzymatycznej związków ketonowych
MX362102B (es) Método para producir 4-[5-(piridin-4-il)-1h-1,2,4-triazol-3-il]pir idina-2-carbonitrilo e intermediario del mismo.
MX353203B (es) Metodo para producir un derivado heterociclico fenilo sustituido por medio del metodo de acoplamiento utilizando un compuesto paladio.
UA106988C2 (uk) Спосіб одержання 1-бензил-3-гідроксиметил-1h-індазолу і його похідних та необхідні проміжні сполуки магнію
EA201390336A1 (ru) Способ получения промежуточного соединения для синтеза лекарственного средства
MX2009004982A (es) Derivados heterociclicos como inhibidores cetp.
TW200738650A (en) Process for synthesis of aryloxy diaminopyrimidines
MX2010009926A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexancarboxilico.
WO2007093877A8 (en) Process for over-production of hydrogen
MX2007013872A (es) Procedimiento para la produccion de 4-bifenililazetidina-2-onas.

Legal Events

Date Code Title Description
FG Grant or registration